Solcitinib (Synonyms: GLPG0778, GSK2586184) |
カタログ番号GC19334 |
ソルシチニブは、経口活性、競合的、強力な選択的 JAK1 阻害剤であり、IC50 は 9.8 nM で、JAK2、JAK3、TYK2 に対してそれぞれ 11、55、23 倍の選択性があります。ソルシチニブは、中等度から重度の尋常性乾癬の研究に使用されています。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1206163-45-2
Sample solution is provided at 25 µL, 10mM.
Solcitinib is an orally active, competitive, potent, selective JAK1 inhibitor, with an IC50 of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively; Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis.
Solcitinib is an orally active, competitive, potent, selective JAK1 inhibitor, with an IC50 of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively. Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis[1].
References:
[1]. Ludbrook VJ, et al. Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study. Br J Dermatol. 2016 May;174(5):985-95.
Average Rating: 5
(Based on Reviews and 18 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *